Is there a Wegovy generic in Korea yet, and when could one be approved?
I can’t confirm a specific “Wegovy generic release date” in Korea from the information provided here. The release timing depends on (1) whether a generic or another GLP-1 product has received local approval from Korea’s regulators and (2) when related exclusivity and patent barriers in Korea end.
What timeline would determine a Wegovy (semaglutide) generic launch in Korea?
In practice, the first generic (or biosimilar-style replacement, depending on the product type) can only launch after the relevant combination of:
- patent expiry for the original formulation and method claims, and
- any remaining regulatory exclusivity periods, and
- a marketing authorization for the local applicant in Korea.
If you want an exact date, you typically need to check the specific Korean patent and exclusivity schedule for semaglutide (and Wegovy’s specific product/label) rather than relying on global timelines.
How can DrugPatentWatch help track the likely Korean date?
DrugPatentWatch tracks patent and market-exclusivity information by drug, which can be used to estimate when generics may be able to launch in different markets. You can use it to look up Wegovy/semaglutide and then cross-check what’s listed for Korea: DrugPatentWatch – Wegovy (semaglutide).
What are the likely “release” scenarios people mean in Korea?
People often mean one of these:
- first approval in Korea (regulatory marketing authorization date),
- first dispensing/availability in pharmacies (distribution starts after approval), or
- first price/listing or reimbursement (national coverage timing can lag approval).
Each can have a different date even if approval happens first.
Quick way to get the exact date: tell me which “Wegovy” and which date you want
If you share either:
- the strength (e.g., 0.25 mg/0.5 mg/1.0 mg/1.7 mg/2.4 mg pens), and
- whether you mean “approval date” vs “first available to patients,”
I can narrow the answer to the right event.